Pamrevlumab did not meet its primary endpoint for ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-2 trial
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
In Duchenne muscular dystrophy (DMD), fibrosis is linked to connective tissue growth factor (CTGF) overexpression. Pamrevlumab, a fully human monoclonal antibody that inhibits CTGF activity, showed promise as a DMD treatment in a phase 2 trial.
Objective
LELANTOS-2 ( NCT04632940 ) was a global phase 3 study of the safety and efficacy of pamrevlumab for ambulatory males 6 to <12 years old with DMD.
Methods
Patients were randomized 1:1 to pamrevlumab 35 mg/kg every 2 weeks for 52 weeks or placebo. All received a stable corticosteroid regimen (deflazacort or prednisone/prednisolone). Primary endpoint was change in North Star Ambulatory Assessment (NSAA) total score from baseline to Week 52. Treatment-emergent adverse events (TEAEs) were noted. Patients who completed the main study period were eligible to enroll in the open-label extension (OLE).
Results
Seventy-three patients enrolled (mean [SD] age, 9.0 [1.5] years; pamrevlumab [n=37], placebo [n=36]). Between-group baseline characteristics were similar. The difference in change in NSAA score was not significant (least squares [LS] mean [SE]: pamrevlumab, –3.022 [0.5505] vs placebo, –2.494 [0.6962]; p =0.5553). Across all secondary endpoints, there were no significant differences between patients treated with pamrevlumab or placebo. Nearly all patients (pamrevlumab, n=35 [97.2%]; placebo, n=35 [97.2%]) experienced TEAEs (most mild/moderate). Sixty-eight (34 from each original treatment group) patients enrolled in and received pamrevlumab during the OLE. OLE efficacy and safety were consistent with the main study period. No deaths occurred.
Conclusions
Pamrevlumab failed to meet its primary endpoint. Its future as a DMD treatment is uncertain.
